ArticleLife (Basel, Switzerland)2026
Randomized Clinical Study of Laser-Assisted Delivery of Exosome Boosters for Postoperative Facial Scars and Facial Rejuvenation.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Postoperative facial scars frequently remain aesthetically problematic despite advances in laser-based treatments, as residual inflammation and disorganized dermal remodeling often limit clinical outcomes. Exosome-based formulations have gained attention as biologically active adjuncts capable of influencing key wound-healing pathways, including inflammatory regulation, neovascularization, and extracellular matrix modulation. This randomized, controlled clinical study aimed to evaluate the short-term clinical effect of laser-assisted delivery of exosome skin boosters for postoperative facial scars and facial rejuvenation. Seventy-five patients with postoperative facial scars were randomly allocated to receive fractional non-ablative Nd:YAG laser treatment alone or in combination with either human-derived or plant-derived exosome skin boosters. All participants completed five treatment sessions at two-week intervals. Clinical outcomes were evaluated using validated scar assessment tools, including the modified Vancouver Scar Scale and the Patient and Observer Scar Assessment Scale, along with objective imaging analyses using Mark-Vu and ImageJ software. Compared with laser monotherapy, adjunctive exosome treatment was associated with numerically greater short-term improvements in scar appearance and reductions in grayscale intensity. Improvements in additional skin quality parameters, such as pigmentation uniformity, erythema, pore size, and fine wrinkles, were also observed in the exosome-treated groups. Clinical responses were comparable between human- and plant-derived exosome formulations, and no serious adverse events were reported. These findings indicate that exosome-based skin boosters may serve as a safe and well-tolerated biological complement to laser therapy for short-term improvement of postoperative facial scars and skin quality. Larger studies with longer follow-up are warranted to determine long-term efficacy and clinical durability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.